The potential role of statins in pneumonia

Brandy Nakashima, Marcos I. Restrepo, Antonio Anzueto, Eric M. Mortensen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
JournalCurrent Respiratory Medicine Reviews
Issue number3
StatePublished - 2010


  • HMG-CoA reductase inhibitor
  • Pneumonia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'The potential role of statins in pneumonia'. Together they form a unique fingerprint.

Cite this